Pantoprazole
Pantoprazole. Irreversible H+/K+-ATPase inhibitor with the smallest CYP2C19 DDI footprint of the PPI class — least clopidogrel interaction.… Oral half-life 1.9 h.
Irreversible H+/K+-ATPase inhibitor with the smallest CYP2C19 DDI footprint of the PPI class — least clopidogrel interaction. CYP2C19 substrate; metabolite further deactivated by sulfotransferase.
PK: the one proton-pump inhibitor whose NUMBERS were right and whose CITATION was wrong. V 11.9 L and F 0.77 are both verbatim in Pue 1993 (PMID:8405016) — "The apparent volume of distribution estimated at steady state (0.17 l.kg-1)" and "the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%)" — a paper already sitting in this record references while the source_pmid pointed at an oral-only genotype study that states neither. That study is also the intravenous arm the row needed. Half-life corrected 1 to the stated 1.9 h. ka 4 dropped: the same paper describes "a variable onset of absorption", a lag rather than a rate, and the lag is a property of the enteric coat that disappears with a bicarbonate suspension. The same effect-decoupling flag as the other two applies.
Pharmacokinetics
- Oral — t½ 1.9 h · F 77% · Vd 11.9 L
- IV — t½ 1.9 h · F 100% · Vd 11.9 L
Sources: PMID:8405016